All News

An analysis of efficacy and safety outcomes in patients receiving perampanel as first adjunctive antiepileptic drug found that almost half of the patients were seizure-free.

A recent study showed that effective lifestyle behavioral changes for patients with chronic kidney disease frequently involved education, goal setting, feedback, monitoring, and social support.

Jelly of the Month might not have impressed Clark Griswold, but we're sure there's a pharmacist on your gift list that would appreciate one of these items.

Researchers used an epidermal growth factor (EGF)-conjugated anthrax toxin that, after targeting EGFR, was internalized and triggered apoptosis in exposed bladder cancer cells.

Top news of the day from across the health care landscape.

Approximately 2 out of 6 study participants tested positive after vaping cannabis that contained 0.39% THC using urine testing methods.

With this approval, enzalutamide is the first and only oral treatment approved by the FDA in 3 distinct types of advanced prostate cancer.

The CDC reported progress with the current status of the 3 strategies within the national initiative, Ending the HIV Epidemic: A Plan for America.

The immunogenicity and safety of hepatitis B surface antigen (HBsAg)/CpG 1018 was assessed in patients with diabetes aged 60 to 70 years.

A retrospective cohort study was the second largest evaluation to date of sodium polystyrene sulphonate use and safety in patients with chronic kidney disease.

What is causing a patient’s memory loss?

Icosapent ethyl is the first FDA-approved prescription form of fish oil to reduce cardiovascular risk among patients with triglyceride levels as an add-on to maximally tolerated statin therapy.

The supplemental new drug application approval expands the patient population who stand to benefit from riluzole to include patients with ALS for whom swallowing is difficult and requires the use of percutaneous endoscopic gastrostomy feeding tube.

Top news of the day from across the health care landscape.

Results of the DAPA-HF trial demonstrate the efficacy and safety of dapagliflozin in patients with heart failure.

In this study, researchers wanted to evaluate the frequency of reduced immunoglobulin concentrations and its association with immunotherapy and disease course in 2 independent cohorts with multiple sclerosis.